Methods for treating and diagnosing Parkinson's disease associated with wild-type LRRK2
Patent Information
- Application Number
- JP2023549961
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-26
- Filing Date
- 2021-10-25
- Publication Date
- 2024-11-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
【0005】 概要 本発明は、患者のゲノムにおけるLRRK2の遺伝的修飾因子を指標として使用して、野生型LRRK2を有するPD患者がLRRK2阻害剤に対して応答する可能性がより高いかどうかを決定する方法を提供する。本発明は、LRRK2の遺伝的修飾因子が、LRRK2キナーゼのレベルもしくは活性の変化、例えば増加もしくは減少を引き起こし得るか、または上流もしくは下流の調節因子を介してLRRK2シグナル伝達経路を別様に変化させることによって、PD病因に寄与し得ることを認識する。その結果、1つまたはそれを超えるそのような修飾因子を有するPD患者は、正常な形態のキナーゼを産生するLRRK2対立遺伝子を有するにもかかわらず、LRRK2阻害剤を使用する薬物療法から利益を得る可能性がある。したがって、LRRK2活性の遺伝的修飾因子は、LRRK2阻害剤療法が所与の個体に適切であるかどうかを決定するための指標として役立つ。本発明の方法は、LRRK2阻害剤療法の候補としてPD患者を同定すること、およびそのような患者を処置することの両方に有用である。
Smart Images

Figure 2022093685000001 
Figure 2022093685000002 
Figure 2022093685000003
Abstract
Claims
1. A composition comprising an LRRK2 inhibitor for treating a subject having Parkinson's disease associated with wild-type LRRK2, characterized in that the composition is provided to a subject exhibiting Parkinson's disease and having wild-type LRRK2 and genetic modifiers of wild-type LRRK2, such that the subject responds to the LRRK2 inhibitor, thereby treating the subject's Parkinson's disease associated with wild-type LRRK2.
2. The composition of claim 1 , wherein the genetic modifier comprises a single nucleotide polymorphism (SNP).
3. The SNPs are rs10784722, rs10877877, rs10879122, rs11181542, rs113111234, rs113736300, rs12230765, rs12816484, rs12829831, rs13377670, rs141551396, rs144377852, rs149173058, rs17580794, rs17621741, rs1838354, rs184120094, rs188535877, rs188583486, rs188604552, rs189517205, rs200611801, rs200907772, rs201889643, rs201944175, rs2406426, rs2406860, rs285561, rs34566033, rs368141132, rs369084695, rs371700002, rs371905892, rs373439540, rs376468815, rs377104202, rs377627337, rs384234, rs61920964, rs6581941, rs6650226, rs71078241, rs7304080, rs73088926, rs74434364, rs74842215, rs75043969, rs78468120, rs7960429, rs7979420, rs76904798, rs57025360, rs112515153, rs10877877, rs10784722, rs4272849, rs2404832, rs117534366, rs1838343, rs10880342, rs11177660, rs183028452, rs116912628, rs147755361, rs11584630, rs3793397, rs111794893, rs4931640, rs526507, rs79307177, rs187116363, rs71609573, rs74390551, rs144665441, rs1718880, rs1991401, rs11052225, rs145801597, rs72907976, rs147286120, rs378690, rs73188365, rs610037, rs75479531, rs1112191556, rs308303, rs10790282, rs3729912, rs4326638,3. The composition of claim 2, wherein the nucleic acid sequence is selected from the group consisting of rs4414548, rs13009437, rs56045011, rs6858566, rs4425, and rs11052253.
4. 2. The composition of claim 1, wherein the LRRK2 inhibitor is selected from the group consisting of CZC-25146, CZC-54252, DNL151, DNL201, GNE-7915, GSK2578215A, HG-10-102-01, JH-II-127, K252A, K252B, LRRK2-IN-1, MLi-2, PF-06447475, and staurosporine.
5. The LRRK2 inhibitor is represented by formula (I), (II), (III), and (IV): [C3-1] [C3-2] A compound selected from the group consisting of: (In the formula, A is NH, O, S, C=O, NR 3 Or CR 4 R 5 and X is an optionally substituted arylene, heteroarylene, cycloalkylene, heterocycloalkylene, alkylcycloalkylene, heteroalkylcycloalkylene, aralkylene, or heteroaralkylene group; R 1 is an optionally substituted alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 2 is a hydrogen atom, a halogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 3 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkyl-cycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 4 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 5 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; B is NH, O, S, C=O, NR 14 or CR 15 R 16 and R 11 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 12 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group, where R 12 is attached to the pyrimidine ring of formula (II) via a carbon-carbon bond; R 13 is a hydrogen atom, a halogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 14 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkyl-cycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 15 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 16 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 21 is aryl or heteroaryl, each of which is optionally substituted; R 22 H, halo, OH, CN, CF 3 , C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Thioalkyl, C 3~8Cycloalkyl, C 2~8 heterocycloalkyl, aryl, or heteroaryl; Y is aryl or 5- or 6-membered heteroaryl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Thioalkyl, C 3~8 Cycloalkyl, C 2~8 Each of heterocycloalkyl, aryl, and heteroaryl is selected from halo, OH, CN, CF 3 , N.H. 2 , NO 2 , C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Thioalkyl, C 3~8 Cycloalkyl, C 2~8 Heterocycloalkyl, C 2~8 Heterocycloalkenyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, C 1~6 Alkylamino, C 2~6 Dialkylamino, C 7~12 Aralkyl, C 1~12 Heteroaralkyl, aryl, heteroaryl, -C(O)R, -C(O)OR, -C(O)NRR', -C(O)NRS(O) 2 R', -C(O)NRS(O) 2 NR'R", -OR, -OC(O)NRR', -NRR', -NRC(O)R', -NRC(O)NR'R", -NRS(O) 2 R', -NRS(O) 2 NR'R", -S(O) 2 R, and -S(O) 2 NRR′ is optionally substituted with one or more moieties selected from the group consisting of: wherein each of R, R′, and R″ is independently H, halo, OH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~8Cycloalkyl, C 2~8 heterocycloalkyl, aryl, or heteroaryl, or R and R', or R' and R", taken together with the nitrogen to which they are attached, are C 2~8 forming a heterocycloalkyl; R 31 is C(O)CH 2 R 33 , optionally substituted cycloalkyl, optionally substituted cycloheteroalkyl, optionally substituted cycloalkenyl, optionally substituted cycloheteroalkenyl, optionally substituted aryl, or optionally substituted heteroaryl; R 32 each instance of is independently halo, haloalkyl, optionally substituted alkoxyl, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted heteroalkenyl; R 33 is optionally substituted cycloalkyl, optionally substituted cycloheteroalkyl, optionally substituted cycloalkenyl, optionally substituted cycloheteroalkenyl, optionally substituted aryl, or optionally substituted heteroaryl; Z is cycloalkyl, cycloheteroalkyl, cycloalkenyl, cycloheteroalkenyl, aryl, or heteroaryl; Z is selected from two or three R 2 Z may be an aryl substituted with two or three R 2 Z may be phenyl substituted with, for example, two or three R 2 Z may be a heteroaryl substituted with, for example, two or three R 2 and may be a 6-membered heteroaryl substituted with, for example, n is 0 to 5); or a pharma- ceutically acceptable salt of any of the above compounds.
6. A method for obtaining one or more genetic modifiers of LRRK2 as an indicator of whether a subject having Parkinson's disease associated with wild-type LRRK2 will respond to an LRRK2 inhibitor, comprising: performing an assay on a sample from said subject having Parkinson's disease associated with wild-type LRRK2 to obtain genetic data from said subject; and generating a report identifying one or more genetic modifiers of LRRK2 in said genetic data. wherein the one or more genetic modifiers indicate that the subject having Parkinson's disease associated with wild-type LRRK2 is responsive to an LRRK2 inhibitor.
7. The method of claim 6 , wherein the genetic data comprises sequence data.
8. The method of claim 7, wherein the genetic modifier comprises a single nucleotide polymorphism (SNP).
9. The SNPs are rs10784722, rs10877877, rs10879122, rs11181542, rs113111234, rs113736300, rs12230765, rs12816484, rs12829831, rs13377670, rs141551396, rs144377852, rs149173058, rs17580794, rs17621741, rs1838354, rs184120094, rs188535877, rs188583486, rs188604552, rs189517205, rs200611801, rs200907772, rs201889643, rs201944175, rs2406426, rs2406860, rs285561, rs34566033, rs368141132, rs369084695, rs371700002, rs371905892, rs373439540, rs376468815, rs377104202, rs377627337, rs384234, rs61920964, rs6581941, rs6650226, rs71078241, rs7304080, rs73088926, rs74434364, rs74842215, rs75043969, rs78468120, rs7960429, rs7979420, rs76904798, rs57025360, rs112515153, rs10877877, rs10784722, rs4272849, rs2404832, rs117534366, rs1838343, rs10880342, rs11177660, rs183028452, rs116912628, rs147755361, rs11584630, rs3793397, rs111794893, rs4931640, rs526507, rs79307177, rs187116363, rs71609573, rs74390551, rs144665441, rs1718880, rs1991401, rs11052225, rs145801597, rs72907976, rs147286120, rs378690, rs73188365, rs610037, rs75479531, rs1112191556, rs308303, rs10790282, rs3729912, rs4326638,9. The method of claim 8, wherein the nucleic acid sequence is selected from the group consisting of rs4414548, rs13009437, rs56045011, rs6858566, rs4425, and rs11052253.
10. The method of claim 6, comprising identifying multiple genetic modifiers of LRRK2.
11. 7. The method of claim 6, wherein the LRRK2 inhibitor is selected from the group consisting of CZC-25146, CZC-54252, DNL151, DNL201, GNE-7915, GSK2578215A, HG-10-102-01, JH-II-127, K252A, K252B, LRRK2-IN-1, MLi-2, PF-06447475, and staurosporine.
12. The LRRK2 inhibitor is represented by formula (I), (II), (III), and (IV): [C4] A compound selected from the group consisting of: (In the formula, A is NH, O, S, C=O, NR 3 or CR 4 R 5 and X is an optionally substituted arylene, heteroarylene, cycloalkylene, heterocycloalkylene, alkylcycloalkylene, heteroalkylcycloalkylene, aralkylene, or heteroaralkylene group; R 1 is an optionally substituted alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 2 is a hydrogen atom, a halogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 3 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkyl-cycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 4 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 5 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; B is NH, O, S, C=O, NR 14 Or CR 15 R 16 and R 11 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 12 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group, where R 12 is attached to the pyrimidine ring of formula (II) via a carbon-carbon bond; R 13 is a hydrogen atom, a halogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 14 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkyl-cycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 15 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 16 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 21 is aryl or heteroaryl, each of which is optionally substituted; R 22 H, halo, OH, CN, CF 3 , C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Thioalkyl, C 3~8Cycloalkyl, C 2~8 heterocycloalkyl, aryl, or heteroaryl; Y is aryl or 5- or 6-membered heteroaryl; Here, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Thioalkyl, C 3~8 Cycloalkyl, C 2~8 Each of heterocycloalkyl, aryl, and heteroaryl is selected from halo, OH, CN, CF 3 , N.H. 2 , NO 2 , C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Thioalkyl, C 3~8 Cycloalkyl, C 2~8 Heterocycloalkyl, C 2~8 Heterocycloalkenyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, C 1~6 Alkylamino, C 2~6 Dialkylamino, C 7~12 Aralkyl, C 1~12 Heteroaralkyl, aryl, heteroaryl, -C(O)R, -C(O)OR, -C(O)NRR', -C(O)NRS(O) 2 R', -C(O)NRS(O) 2 NR'R", -OR, -OC(O)NRR', -NRR', -NRC(O)R', -NRC(O)NR'R", -NRS(O) 2 R', -NRS(O) 2 NR'R", -S(O) 2 R, and -S(O) 2 NRR′ is optionally substituted with one or more moieties selected from the group consisting of: wherein each of R, R′, and R″ is independently H, halo, OH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~8 Cycloalkyl, C 2~8 heterocycloalkyl, aryl, or heteroaryl, or R and R', or R' and R", taken together with the nitrogen to which they are attached, are C 2~8 forming a heterocycloalkyl; R 31 is C(O)CH 2 R 33 , optionally substituted cycloalkyl, optionally substituted cycloheteroalkyl, optionally substituted cycloalkenyl, optionally substituted cycloheteroalkenyl, optionally substituted aryl, or optionally substituted heteroaryl; R 32 each instance of is independently halo, haloalkyl, optionally substituted alkoxyl, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted heteroalkenyl; R 33 is optionally substituted cycloalkyl, optionally substituted cycloheteroalkyl, optionally substituted cycloalkenyl, optionally substituted cycloheteroalkenyl, optionally substituted aryl, or optionally substituted heteroaryl; Z is cycloalkyl, cycloheteroalkyl, cycloalkenyl, cycloheteroalkenyl, aryl, or heteroaryl; n is 0 to 5); or a pharma- ceutically acceptable salt of any of the above compounds.
13. 1. A composition comprising an LRRK2 inhibitor for use in a method of treating a subject having Parkinson's disease associated with wild-type LRRK2, the method comprising: receiving genetic data identifying one or more genetic modifiers of LRRK2, wherein the one or more genetic modifiers indicate that a subject having Parkinson's disease associated with wild-type LRRK2 is responsive to an LRRK2 inhibitor; Prescribing or providing said composition to said subject. A composition comprising:
14. The composition of claim 13 , wherein the genetic data is received in the form of a report.
15. The composition of claim 14 , wherein the genetic data comprises sequence data.
16. The composition of claim 15 , wherein the genetic modifier comprises a single nucleotide polymorphism (SNP).
17. The SNPs are rs10784722, rs10877877, rs10879122, rs11181542, rs113111234, rs113736300, rs12230765, rs12816484, rs12829831, rs13377670, rs141551396, rs144377852, rs149173058, rs17580794, rs17621741, rs1838354, rs184120094, rs188535877, rs188583486, rs188604552, rs189517205, rs200611801, rs200907772, rs201889643, rs201944175, rs2406426, rs2406860, rs285561, rs34566033, rs368141132, rs369084695, rs371700002, rs371905892, rs373439540, rs376468815, rs377104202, rs377627337, rs384234, rs61920964, rs6581941, rs6650226, rs71078241, rs7304080, rs73088926, rs74434364, rs74842215, rs75043969, rs78468120, rs7960429, rs7979420, rs76904798, rs57025360, rs112515153, rs10877877, rs10784722, rs4272849, rs2404832, rs117534366, rs1838343, rs10880342, rs11177660, rs183028452, rs116912628, rs147755361, rs11584630, rs3793397, rs111794893, rs4931640, rs526507, rs79307177, rs187116363, rs71609573, rs74390551, rs144665441, rs1718880, rs1991401, rs11052225, rs145801597, rs72907976, rs147286120, rs378690, rs73188365, rs610037, rs75479531, rs1112191556, rs308303, rs10790282, rs3729912, rs4326638,17. The composition of claim 16, wherein the nucleic acid sequence is selected from the group consisting of rs4414548, rs13009437, rs56045011, rs6858566, rs4425, and rs11052253.
18. The composition of claim 13, wherein the method comprises identifying multiple genetic modifiers of LRRK2.
19. 14. The composition of claim 13, wherein the LRRK2 inhibitor is selected from the group consisting of CZC-25146, CZC-54252, DNL151, DNL201, GNE-7915, GSK2578215A, HG-10-102-01, JH-II-127, K252A, K252B, LRRK2-IN-1, MLi-2, PF-06447475, and staurosporine.
20. The LRRK2 inhibitor has formula (I), (II), (III), or (IV): [C5-1] [C5-2] A compound selected from the group consisting of: (In the formula, A is NH, O, S, C=O, NR 3 or CR 4 R 5 and X is an optionally substituted arylene, heteroarylene, cycloalkylene, heterocycloalkylene, alkylcycloalkylene, heteroalkylcycloalkylene, aralkylene, or heteroaralkylene group; R 1 is an optionally substituted alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 2 is a hydrogen atom, a halogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 3 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkyl-cycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 4 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 5 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; B is NH, O, S, C=O, NR 14 or CR 15 R 16 and R 11 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 12 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group, where R 12 is attached to the pyrimidine ring of formula (II) via a carbon-carbon bond; R 13 is a hydrogen atom, a halogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 14 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkyl-cycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 15 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 16 is a hydrogen atom, NO 2 , N 3 , O.H., S.H., and N.H. 2 or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group; R 21 is aryl or heteroaryl, each of which is optionally substituted; R 22 H, halo, OH, CN, CF 3 , C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Thioalkyl, C 3~8Cycloalkyl, C 2~8 heterocycloalkyl, aryl, or heteroaryl; Y is aryl or 5- or 6-membered heteroaryl; Here, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Thioalkyl, C 3~8 Cycloalkyl, C 2~8 Each of heterocycloalkyl, aryl, and heteroaryl is selected from halo, OH, CN, CF 3 , N.H. 2 , NO 2 , C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Thioalkyl, C 3~8 Cycloalkyl, C 2~8 Heterocycloalkyl, C 2~8 Heterocycloalkenyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, C 1~6 Alkylamino, C 2~6 Dialkylamino, C 7~12 Aralkyl, C 1~12 Heteroaralkyl, aryl, heteroaryl, -C(O)R, -C(O)OR, -C(O)NRR', -C(O)NRS(O) 2 R', -C(O)NRS(O) 2 NR'R", -OR, -OC(O)NRR', -NRR', -NRC(O)R', -NRC(O)NR'R", -NRS(O) 2 R', -NRS(O) 2 NR'R", -S(O) 2 R, and -S(O) 2 NRR′ is optionally substituted with one or more moieties selected from the group consisting of: wherein each of R, R′, and R″ is independently H, halo, OH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~8 Cycloalkyl, C 2~8 heterocycloalkyl, aryl, or heteroaryl, or R and R', or R' and R", taken together with the nitrogen to which they are attached, are C 2~8 Forming a heterocycloalkyl; R 31 is C(O)CH 2 R 33 , optionally substituted cycloalkyl, optionally substituted cycloheteroalkyl, optionally substituted cycloalkenyl, optionally substituted cycloheteroalkenyl, optionally substituted aryl, or optionally substituted heteroaryl; R 32 each instance of is independently halo, haloalkyl, optionally substituted alkoxyl, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted heteroalkenyl; R 33 is optionally substituted cycloalkyl, optionally substituted cycloheteroalkyl, optionally substituted cycloalkenyl, optionally substituted cycloheteroalkenyl, optionally substituted aryl, or optionally substituted heteroaryl; Z is cycloalkyl, cycloheteroalkyl, cycloalkenyl, cycloheteroalkenyl, aryl, or heteroaryl; n is 0 to 5); or a pharma- ceutically acceptable salt of any of the above compounds.
